---
input_text: 'Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A
  Encephalopathy and Dravet Syndrome. OBJECTIVE: SCN8A encephalopathy is a developmental
  and epileptic encephalopathy (DEE) caused by de novo gain-of-function mutations
  of sodium channel Nav 1.6 that result in neuronal hyperactivity. Affected individuals
  exhibit early onset drug-resistant seizures, developmental delay, and cognitive
  impairment. This study was carried out to determine whether reducing the abundance
  of the Scn8a transcript with an antisense oligonucleotide (ASO) would delay seizure
  onset and prolong survival in a mouse model of SCN8A encephalopathy. METHODS: ASO
  treatment was tested in a conditional mouse model with Cre-dependent expression
  of the pathogenic patient SCN8A mutation p.Arg1872Trp (R1872W). This model exhibits
  early onset of seizures, rapid progression, and 100% penetrance. An Scn1a +/- haploinsufficient
  mouse model of Dravet syndrome was also treated. ASO was administered by intracerebroventricular
  injection at postnatal day 2, followed in some cases by stereotactic injection at
  postnatal day 30. RESULTS: We observed a dose-dependent increase in length of survival
  from 15 to 65 days in the Scn8a-R1872W/+ mice treated with ASO. Electroencephalographic
  recordings were normal prior to seizure onset. Weight gain and activity in an open
  field were unaffected, but treated mice were less active in a wheel running assay.
  A single treatment with Scn8a ASO extended survival of Dravet syndrome mice from
  3 weeks to >5 months. INTERPRETATION: Reduction of Scn8a transcript by 25 to 50%
  delayed seizure onset and lethality in mouse models of SCN8A encephalopathy and
  Dravet syndrome. Reduction of SCN8A transcript is a promising approach to treatment
  of intractable childhood epilepsies. Ann Neurol 2020;87:339-346.'
raw_completion_output: |-
  primary_disease: SCN8A encephalopathy

  medical_actions: Administration of Scn8a Antisense Oligonucleotide; Intracerebroventricular injection; Stereotactic injection; Electroencephalographic recordings

  symptoms: Early onset drug-resistant seizures; Developmental delay; Cognitive impairment; Seizure onset; Lethality

  chemicals: Scn8a Antisense Oligonucleotide

  action_annotation_relationships: Administration of Scn8a Antisense Oligonucleotide TREATS early onset drug-resistant seizures IN SCN8A encephalopathy; Administration of Scn8a Antisense Oligonucleotide TREATS developmental delay IN SCN8A encephalopathy; Administration of Scn8a Antisense Oligonucleotide TREATS cognitive impairment IN SCN8A encephalopathy; Intracerebroventricular injection (with Scn8a Antisense Oligonucleotide) PREVENTS seizure onset IN SCN8A encephalopathy; Stereotactic injection (with Scn8a Antisense Oligonucleotide) PREVENTS lethality IN SCN8A encephalopathy
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Stereotactic injection (with Scn8a Antisense Oligonucleotide) PREVENTS lethality IN SCN8A encephalopathy

  ===

extracted_object:
  primary_disease: MONDO:0013801
  medical_actions:
    - Administration of Scn8a Antisense Oligonucleotide
    - Intracerebroventricular injection
    - Stereotactic injection
    - Electroencephalographic recordings
  symptoms:
    - Early onset drug-resistant seizures
    - HP:0001263
    - HP:0100543
    - Seizure onset
    - Lethality
  chemicals:
    - Scn8a Antisense Oligonucleotide
  action_annotation_relationships:
    - subject: Administration
      predicate: TREATS
      object: early onset drug-resistant seizures
      qualifier: MONDO:0013801
      subject_extension: Scn8a Antisense Oligonucleotide
    - subject: Administration
      predicate: TREATS
      object: HP:0001263
      qualifier: MONDO:0013801
      subject_extension: Scn8a Antisense Oligonucleotide
    - subject: Administration
      predicate: TREATS
      object: HP:0100543
      qualifier: MONDO:0013801
      subject_extension: Scn8a Antisense Oligonucleotide
    - subject: Intracerebroventricular injection
      predicate: PREVENTS
      object: seizure onset
      qualifier: MONDO:0013801
      subject_qualifier: with Scn8a Antisense Oligonucleotide
      subject_extension: Scn8a Antisense Oligonucleotide
    - subject: Stereotactic injection
      predicate: PREVENTS
      object: lethality
      qualifier: MONDO:0013801
      subject_qualifier: with Scn8a Antisense Oligonucleotide
      subject_extension: Scn8a Antisense Oligonucleotide
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
